SEC Form 4 · accession 0001209191-19-019213
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander O. Schuth
Officer — COO and Secretary
Period of report
Mar 11, 2019
Accepted (ET)
Mar 13, 2019 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Mar 11, 2019 | S | 2,200 | $21.20 | D | 660,389 | I | See footnote |
| Common StockF4,F3 | Mar 11, 2019 | S | 275 | $21.80 | D | 660,114 | I | See footnote |
| Common StockF5,F3 | Mar 12, 2019 | S | 2,513 | $22.40 | D | 657,601 | I | See footnote |
| Common StockF6,F3 | Mar 13, 2019 | S | 1,000 | $23.60 | D | 656,601 | I | See footnote |
| Common StockF7,F3 | Mar 13, 2019 | S | 1,512 | $24.33 | D | 655,089 | I | See footnote |
| Common Stock | holding | — | — | — | 15,738 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F2The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.73 to $21.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee.
- F4The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.79 to $21.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F5The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.01 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F6The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.04 to $24.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F7The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.09 to $24.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.